Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis After a First Demyelinating Event
NEJM 349:139-145,107, Berger,T.,et al, 2003
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Multiple Sclerosis Masquerading as a Mass Lesion
Neuroradiolgoy 34:150-154, Giang,D.W.,et al, 1992